Logo image of UPC

UNIVERSE PHARMACEUTICALS INC (UPC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:UPC - KYG9442G1385 - Common Stock

4.31 USD
+0.09 (+2.13%)
Last: 1/9/2026, 8:00:01 PM
4.17 USD
-0.14 (-3.25%)
After Hours: 1/9/2026, 8:00:01 PM
Fundamental Rating

3

Overall UPC gets a fundamental rating of 3 out of 10. We evaluated UPC against 191 industry peers in the Pharmaceuticals industry. While UPC seems to be doing ok healthwise, there are quite some concerns on its profitability. UPC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

UPC had positive earnings in the past year.
UPC had a negative operating cash flow in the past year.
In multiple years UPC reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: UPC reported negative operating cash flow in multiple years.
UPC Yearly Net Income VS EBIT VS OCF VS FCFUPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

1.2 Ratios

UPC has a Return On Assets of 1.35%. This is amongst the best in the industry. UPC outperforms 80.63% of its industry peers.
UPC's Return On Equity of 1.97% is amongst the best of the industry. UPC outperforms 81.68% of its industry peers.
Industry RankSector Rank
ROA 1.35%
ROE 1.97%
ROIC N/A
ROA(3y)-14.43%
ROA(5y)-0.18%
ROE(3y)-20.51%
ROE(5y)-1.19%
ROIC(3y)N/A
ROIC(5y)N/A
UPC Yearly ROA, ROE, ROICUPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

UPC's Profit Margin of 5.65% is amongst the best of the industry. UPC outperforms 82.20% of its industry peers.
UPC's Gross Margin of 30.41% is in line compared to the rest of the industry. UPC outperforms 57.59% of its industry peers.
In the last couple of years the Gross Margin of UPC has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 5.65%
GM 30.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.65%
GM growth 5Y-8.51%
UPC Yearly Profit, Operating, Gross MarginsUPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

4

2. Health

2.1 Basic Checks

UPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for UPC has been increased compared to 1 year ago.
UPC has more shares outstanding than it did 5 years ago.
UPC has a better debt/assets ratio than last year.
UPC Yearly Shares OutstandingUPC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
UPC Yearly Total Debt VS Total AssetsUPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.37, we must say that UPC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of UPC (0.37) is comparable to the rest of the industry.
UPC has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
UPC has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 0.37
ROIC/WACCN/A
WACC6.45%
UPC Yearly LT Debt VS Equity VS FCFUPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 2.78 indicates that UPC has no problem at all paying its short term obligations.
UPC's Current ratio of 2.78 is in line compared to the rest of the industry. UPC outperforms 49.74% of its industry peers.
A Quick Ratio of 2.62 indicates that UPC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.62, UPC is in line with its industry, outperforming 53.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.62
UPC Yearly Current Assets VS Current LiabilitesUPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

UPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.13%, which is quite impressive.
Looking at the last year, UPC shows a very negative growth in Revenue. The Revenue has decreased by -27.81% in the last year.
UPC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.08% yearly.
EPS 1Y (TTM)106.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.56%
Revenue 1Y (TTM)-27.81%
Revenue growth 3Y-21.71%
Revenue growth 5Y-7.08%
Sales Q2Q%-28.96%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UPC Yearly Revenue VS EstimatesUPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

UPC is valuated cheaply with a Price/Earnings ratio of 0.02.
Compared to the rest of the industry, the Price/Earnings ratio of UPC indicates a rather cheap valuation: UPC is cheaper than 100.00% of the companies listed in the same industry.
UPC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
Industry RankSector Rank
PE 0.02
Fwd PE N/A
UPC Price Earnings VS Forward Price EarningsUPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UPC Per share dataUPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100 150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

UPC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

UNIVERSE PHARMACEUTICALS INC

NASDAQ:UPC (1/9/2026, 8:00:01 PM)

After market: 4.17 -0.14 (-3.25%)

4.31

+0.09 (+2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2022-02-11/dmh
Earnings (Next)N/A N/A
Inst Owners0.36%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.41M
Revenue(TTM)19.29M
Net Income(TTM)1.09M
Analysts0
Price TargetN/A
Short Float %2.35%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.02
Fwd PE N/A
P/S 0.13
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)191.57
EY4444.78%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-21.51
FCFYN/A
OCF(TTM)-20.76
OCFYN/A
SpS34.45
BVpS98.54
TBVpS98.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number651.74
Profitability
Industry RankSector Rank
ROA 1.35%
ROE 1.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 5.65%
GM 30.41%
FCFM N/A
ROA(3y)-14.43%
ROA(5y)-0.18%
ROE(3y)-20.51%
ROE(5y)-1.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.65%
GM growth 5Y-8.51%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 82.09%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.62
Altman-Z 0.37
F-Score5
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)30.9%
Cap/Depr(5y)40.54%
Cap/Sales(3y)0.59%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.81%
Revenue growth 3Y-21.71%
Revenue growth 5Y-7.08%
Sales Q2Q%-28.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-352.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-342.11%
OCF growth 3YN/A
OCF growth 5YN/A

UNIVERSE PHARMACEUTICALS INC / UPC FAQ

What is the ChartMill fundamental rating of UNIVERSE PHARMACEUTICALS INC (UPC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to UPC.


Can you provide the valuation status for UNIVERSE PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSE PHARMACEUTICALS INC (UPC). This can be considered as Overvalued.


How profitable is UNIVERSE PHARMACEUTICALS INC (UPC) stock?

UNIVERSE PHARMACEUTICALS INC (UPC) has a profitability rating of 3 / 10.


What is the valuation of UNIVERSE PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for UNIVERSE PHARMACEUTICALS INC (UPC) is 0.02 and the Price/Book (PB) ratio is 0.04.